A Phase 2 interventional study of DCV/ASV/BMS-791325 and Ribavirin in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 7 sites in United States. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.
Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 45th largest by enrollment, is one of 13 that started in 2014, is one of 17 in phase 2, and was the 38th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 18 · Phase 3 25 · Phase 4 5
First in 2009; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 100 across the 59 interventional studies. Of the 53 that completed or were terminated, 25 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 59 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
78 studies in Hepatitis C by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 70 finished, 25 (36%) have results posted.
Among the 78 studies in Hepatitis C by Bristol-Myers Squibb, this one is the 52nd largest by enrollment of the 67 interventional ones that give a count, is one of 20 that started in 2014, is one of 20 in phase 2, and was the 63rd registered.
Bristol-Myers Squibb’s Hepatitis C studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing daclatasvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 78 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
Allocation:
Initial Therapy: Randomized Controlled Trial: Participants are assigned to intervention groups by chance
Rescue Therapy: Nonrandomized Trial: Participants are expressly assigned to intervention groups through a non-random method such as physician choice
Number of Arms:
Initial Therapy: 2 Groups
Rescue Therapy: 2 Groups
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial Therapy: Daclatasvir/Asunaprevir/BMS-791325 \[30 mg (as the free base)/200 mg/75 mg (as the free base)\] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks Sofosbuvir 400 mg tablet once daily orally for 4 weeks
Drug: DCV/ASV/BMS-791325 · Drug: Sofosbuvir
Initial Therapy Daclatasvir/Asunaprevir/BMS-791325 \[30 mg (as the free base)/200 mg/75 mg (as the free base)\] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks Sofosbuvir 400 mg tablet once daily orally for 6 weeks
Drug: DCV/ASV/BMS-791325 · Drug: Sofosbuvir
Daclatasvir/Asunaprevir/BMS-791325 \[30 mg (as the free base)/200 mg/75 mg (as the free base)\] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks
Drug: DCV/ASV/BMS-791325 · Drug: Ribavirin · Drug: Peginterferon α-2a
Sofosbuvir 400 mg tablet once daily orally for 12 weeks Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks
Drug: Ribavirin · Drug: Sofosbuvir · Drug: Peginterferon α-2a
Drug pages: Daclatasvir · Asunaprevir · Beclabuvir
Also known as: Sovaldi®
Percentage of Participants With Sustained Virologic Response 12 (SVR12)
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantitation (LLOQ) target detected (TD) or not detected (TND) at post-treatment follow-up Week 12. Imputed SVR12 was based on Next Value Carried Backwards approach.
Time frame: 12 Weeks after treatment discontinuation (Follow-up Week 12)
Number of Participants With Deaths, Serious Adverse Events (SAEs) and AEs Leading to Discontinuation From Treatment
SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect.
Time frame: From signature of the informed consent until 4 weeks after last treatment administration.(Approximately 17 months)
Number of Participants With Selected Grade 3/4 Laboratory Abnormalities
Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 24 data set was used to evaluate the Week-24 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death.
Time frame: From signature of the informed consent until 4 weeks after last treatment administration.(Approximately 17 months)
Percentage of Participants With End of Treatment Response (EOTR)
EOTR was defined as HCV RNA less than the lower limit of quantitation, target detected or not detected at end of treatment.
Time frame: End of the treatment
Percentage of Participants Who Achieved HCV RNA <LLOQ TD/TND
Percentage of Participants with hepatitis C virus(HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) were presented at treatment Weeks 1, 2, 4, 6, and follow-up Weeks 2 (SVR2), 4 (SVR4), 12 (SVR12) and 24 (SVR24).
Time frame: Treatment Weeks 1, 2, 4 and 6; post-treatment Weeks 2 (SVR2), 4 (SVR4), 12 (SVR12) and 24 (SVR24)
Percentage of Participants Who Achieved HCV RNA < LLOQ TND
Percentage of Participants with hepatitis C virus(HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target not detected (TND) were presented at treatment Weeks 1, 2, 4, 6, and follow-up Weeks 2 (SVR2), 4 (SVR4), and 24 (SVR24).
Time frame: Treatment Weeks 1, 2, 4 and 6; post-treatment Weeks 2, 4, 12 and 24
Percentage of Participants Who Achieved SVR12 Associated With HCV Geno Subtype 1a vs 1b
Percentage of Participants who Achieved SVR12 Associated with HCV geno subtype 1a or 1b
Time frame: Post-treatment Week 12
Percentage of Participants Who Achieved SVR12 Associated With Interleukin-28B (IL28B) rs12979860 SNP Status (CC Genotype or Non-CC Genotype)
Percentage of Participants who Achieved SVR12 Associated with IL28B rs12979860 Single Nucleotide Polymorphisms (SNP) status (CC genotype or non CC genotype) were reported.
Time frame: Post-treatment Week 12
| Milestone | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Started | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
| Milestone | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Started | 14 | 14 |
| Completed | 4 | 8 |
| Not completed | 10 | 6 |
| Withdrew: Lack of efficacy | 10 | 6 |
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantitation (LLOQ) target detected (TD) or not detected (TND) at post-treatment follow-up Week 12. Imputed SVR12 was based on Next Value Carried Backwards approach.
| Percentage of participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 (SVR12) | 28.6 (13.1 to 49.2) | 57.1 (36.9 to 75.7) |
EOTR was defined as HCV RNA less than the lower limit of quantitation, target detected or not detected at end of treatment.
| Percentage of participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Percentage of Participants With End of Treatment Response (EOTR) | 92.9 (66.1 to 99.8) | 100.0 (76.8 to 100.0) |
SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/ birth defect.
| Participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Death | 0 | 0 |
| Serious Adverse Events | 1 | 0 |
| AEs Leading to Discontinuation | 0 | 0 |
Grade 3/4 laboratory abnormalities (hematology, electrolyte, lipase, liver function, metabolic, renal function, urinalysis). The Week 24 data set was used to evaluate the Week-24 on-treatment safety. The cumulative data set was used to evaluate the safety while on treatment. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Grades:1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death.
| Participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Number of Participants With Selected Grade 3/4 Laboratory Abnormalities | 0 | 0 |
Percentage of Participants with hepatitis C virus(HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) were presented at treatment Weeks 1, 2, 4, 6, and follow-up Weeks 2 (SVR2), 4 (SVR4), 12 (SVR12) and 24 (SVR24).
| Percentage of Participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Week 1 | 35.7 (12.8 to 64.9) | 71.4 (41.9 to 91.6) |
| Week 2 | 78.6 (49.2 to 95.3) | 100.0 (76.8 to 100.0) |
| Week 4 | 100.0 (76.8 to 100.0) | 100.0 (76.8 to 100.0) |
| Week 6 | NA (NA to NA) | 100.0 (76.8 to 100.0) |
| Follow-Up Week 2 | 78.6 (49.2 to 95.3) | 100.0 (76.8 to 100.0) |
| Follow-Up Week 4 | 42.9 (17.7 to 71.1) | 78.6 (49.2 to 95.3) |
| Follow-Up Week 12 | 28.6 (8.4 to 58.1) | 57.1 (28.9 to 82.3) |
| Follow-Up Week 24 | 28.6 (8.4 to 58.1) | 57.1 (28.9 to 82.3) |
Percentage of Participants with hepatitis C virus(HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target not detected (TND) were presented at treatment Weeks 1, 2, 4, 6, and follow-up Weeks 2 (SVR2), 4 (SVR4), and 24 (SVR24).
| Percentage of participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Week 1 | 21.4 (4.7 to 50.8) | 7.1 (0.2 to 33.9) |
| Week 2 | 42.9 (17.7 to 71.1) | 64.3 (35.1 to 87.2) |
| Week 4 | 92.9 (66.1 to 99.8) | 100.0 (76.8 to 100.0) |
| Week 6 | NA (NA to NA) | 100.0 (76.8 to 100.0) |
| Follow-Up Week 2 | 71.4 (41.9 to 91.6) | 92.9 (66.1 to 99.8) |
| Follow-Up Week 4 | 42.9 (17.7 to 71.1) | 71.4 (41.9 to 91.6) |
| Follow-Up Week 12 | 28.6 (8.4 to 58.1) | 57.1 (28.9 to 82.3) |
| Follow-Up Week 24 | 28.6 (8.4 to 58.1) | 57.1 (28.9 to 82.3) |
Percentage of Participants who Achieved SVR12 Associated with HCV geno subtype 1a or 1b
| Percentage of Participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| Genotype 1a | 27.3 | 54.5 |
| Genotype 1b | 33.3 | 66.7 |
Percentage of Participants who Achieved SVR12 Associated with IL28B rs12979860 Single Nucleotide Polymorphisms (SNP) status (CC genotype or non CC genotype) were reported.
| Percentage of Participants | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| CC genotype | 40.0 | 66.7 |
| Non-CC Genotype | 22.2 | 50.0 |
Collected over All AEs were collected from signature of the informed consent until 4 weeks after last treatment administration.(Approximately 17 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 4 Weeks DCV 3DAA + SOF | 0/14 (0%) | 1/14 (7.1%) | 5/14 (35.7%) |
| 6 Weeks DCV 3DAA + SOF | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| Event | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 1/14 | 0/14 |
| Event | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF |
|---|---|---|
| FATIGUEGeneral disorders | 3/14 | 4/14 |
| HEADACHENervous system disorders | 2/14 | 3/14 |
| NAUSEAGastrointestinal disorders | 2/14 | 1/14 |
| INSOMNIAPsychiatric disorders | 0/14 | 2/14 |
| CHEST DISCOMFORTGeneral disorders | 0/14 | 1/14 |
| CHILLSGeneral disorders | 1/14 | 0/14 |
| OEDEMA PERIPHERALGeneral disorders | 1/14 | 0/14 |
| PYREXIAGeneral disorders | 1/14 | 0/14 |
| DIARRHOEAGastrointestinal disorders | 1/14 | 1/14 |
| CONSTIPATIONGastrointestinal disorders | 0/14 | 1/14 |
All treated participants.
| Age, Continuous(years) | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF | Total |
|---|---|---|---|
| Median | 58.0 (21 to 64) | 59.0 (31 to 64) | 58.5 (21 to 64) |
| Sex: Female, Male(Participants) | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 5 | 6 | 11 |
| Race (NIH/OMB)(Participants) | 4 Weeks DCV 3DAA + SOF | 6 Weeks DCV 3DAA + SOF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 12 | 13 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Ran from Jul 2014 to primary completion in Jan 2015, 6 months.
Results were first posted in May 2019, 4 years 4 months after primary completion. A results delay was requested in Mar 2017.
Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 6 months is below that.
Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daclatasvir · Asunaprevir · Beclabuvir · Ribavirin · Sofosbuvir